Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00051012 · ClinicalTrials.gov registry record · Phase 4
Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients
A Phase 4 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 4
- Development phase
- 86
- Enrollment target
NCT00051012 is a Phase 4 study that has completed, run by Eisai. The registered enrollment target is 86 participants.
The verdict
NCT00051012, a Phase 4 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 86 participants
- Enrollment target
Study Summary
The purpose of this study is to provide an opportunity for patients who exhibit progressive disease while receiving placebo on the companion 93-04-11 study to receive ONTAK. It is also designed to determine the effectiveness of ONTAK in Cutaneous T-cell Lymphoma (CTCL) patients whose tumors do not express CD25.
Interventions
- DRUG ONTAK
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 1995-09 |
| Est. Completion | 2006-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00051012
The ClinicalTrials.gov registry entry for NCT00051012 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ONTAK is the first listed.
NCT00051012 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00051012 about?
NCT00051012 is a clinical study titled "Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients". The purpose of this study is to provide an opportunity for patients who exhibit progressive disease while receiving placebo on the companion 93-04-11 study to receive ONTAK. It is also designed to determine the effectiveness of ONTAK in Cutaneous T-cell Lymphoma (CTCL) patients whose tumors do not e...
What is the current status of trial NCT00051012?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 86 participants. The study started on 1995-09. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00051012?
The interventions under investigation include: ONTAK (DRUG).
Who is sponsoring clinical trial NCT00051012?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.